Core Viewpoint - The Schall Law Firm is investigating Quipt Home Medical Corp. for potential violations of securities laws, particularly concerning misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Quipt issued false or misleading statements, particularly regarding a press release on May 21, 2025, related to an acquisition offer from Forager Capital Management [2]. - Forager Capital Management, a significant shareholder, has requested Quipt to retract its misleading statement about their offer to acquire 100% of Quipt's common shares at a price of $3.10 per share [2]. - Following the news of the investigation and the press release from Forager, Quipt's shares experienced a decline of over 8.5% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Quipt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 5, ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is representing investors of Quipt Home Medical Corp in an investigation regarding possible securities fraud [1] - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a misleading statement related to its acquisition offer [2] Group 2: Stock Performance - Following the news of Forager's request, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation on behalf of investors of Quipt Home Medical Corp regarding possible securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1] Group 2: Shareholder Actions - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a statement made on May 21, 2025, which they claim is false and misleading regarding an acquisition offer [3] - Following the press release from Forager, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [3]

LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed’s presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host’s main website: http ...

Core Viewpoint - Quipt Home Medical Corp. has received an unsolicited non-binding proposal from Forager Capital Management to acquire 100% of its common shares at a price of $3.10 per share [1] Group 1: Proposal Details - The proposal is non-binding, conditional, and indicative, indicating that it is not a formal offer yet [1] - The Company has a Non-Disclosure and Standstill Agreement with Forager, which prohibits Forager from acquiring any equity securities or assets of Quipt for six months without prior approval from the Board [2] - The Board has not provided any prior written approval for the proposal, adhering to the terms of the Agreement [2] Group 2: Company Strategy and Operations - Quipt focuses on providing in-home monitoring and disease management services, particularly in respiratory care, and aims to expand its offerings for chronic disease management [4] - The primary business objective is to create shareholder value by offering a broader range of services to patients, thereby increasing annual revenue per patient [4] - The Company is committed to driving sustainable value for its shareholders and will consult with financial and legal advisors regarding the proposal [3]

LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing ...

AdaptHealth Corp. (NASDAQ:AHCO) Q4 2024 Earnings Conference Call February 25, 2025 8:30 AM ET Company Participants Suzanne Foster – Chief Executive Officer Jason Clemens – Chief Financial Officer Conference Call Participants Ben Hendrix – RBC Capital Markets Mathew Blackman – Stifel Brian Tanquilut – Jefferies Richard Close – Canaccord Eric Coldwell – Baird Kieran Ryan – Deutsche Bank Operator Good day, everyone and welcome to today's AdaptHealth Fourth Quarter 2024 Earnings Release. Today's speakers will b ...